Research programme: depression therapy - Abiogen

Drug Profile

Research programme: depression therapy - Abiogen

Alternative Names: ABIO 09/01; ABIO 0901

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Reading
  • Developer Abiogen Pharma
  • Class Antidepressants; Anxiolytics; Isoxazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Italy
  • 11 Aug 2010 BTG 1675A is still in Preclinical trials for Depression in Italy
  • 13 Feb 2008 BTG 1675A is still in Preclinical trials for Depression in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top